Form 4: Moderna CFO James Mock Reports RSU Vesting, Tax Sale

Moderna's Chief Financial Officer, James Mock, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Moderna's Chief Financial Officer, James M. Mock, reported transactions involving the company's common stock and restricted stock units (RSUs).
• On March 5, 2026, Mr. Mock acquired 11,797 shares of common stock through the conversion of restricted stock units.
• Concurrently, 5,704 shares of common stock were disposed of at a price of $57.8 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Mock beneficially owns 56,998 shares of common stock directly and 129,774 derivative securities (Restricted Stock Units) directly.
• The restricted stock units convert into common stock on a one-for-one basis.
• The RSU award's vesting schedule included 25% vesting on December 5, 2025, with the remaining portion vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation and tax management rather than a discretionary investment decision or a reflection of company performance.

Positives

• The vesting of restricted stock units indicates the fulfillment of compensation incentives for the Chief Financial Officer.
• The acquisition of 11,797 shares of common stock through RSU conversion increases the CFO's direct equity stake in the company, aligning his interests with shareholders.

Negatives

• The disposition of 5,704 shares, although for tax purposes, represents a reduction in the CFO's direct common stock holdings.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing. The risks are inherent to insider transactions, such as potential misinterpretation by the market.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions, providing transparency into insider holdings and compensation structures. These transactions, particularly those related to RSU vesting and tax-related sales, are common occurrences for executives in the biotechnology and pharmaceutical sectors, reflecting routine compensation events rather than discretionary trading.

Comparison to Industry Standards

• The RSU vesting and subsequent tax-related sale are standard practices for executive compensation in publicly traded companies, including those in the biotech industry like Pfizer, BioNTech, or Johnson & Johnson, where executives often receive equity awards as part of their compensation packages.
• The one-for-one conversion of RSUs to common stock is a typical structure for such awards.
• The practice of withholding shares to cover tax obligations upon vesting is a common mechanism to manage the tax implications for executives.

Related Party Transactions

• The transactions involve the Chief Financial Officer of Moderna, Inc., and are therefore considered related party transactions in the context of insider reporting.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and holdings, which can influence investor confidence. The sale for tax purposes is a routine event and not typically indicative of a lack of confidence.
• Employees: Reflects standard executive compensation practices, which can be a benchmark for other employees' equity awards.

Next Steps

• The remaining 75% of the restricted stock unit award will vest in twelve equal quarterly installments after December 5, 2025.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related sales) for Moderna's CFO. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Moderna, MRNA, Form 4, insider trading, beneficial ownership, restricted stock units, RSU, stock sale, tax withholding, James Mock, Chief Financial Officer, executive compensation